Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma.

Abstract

Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders occur at an increasing frequency in various hereditary and acquired states of immune dysfunction. In a few cases of T-cell lymphoma, especially in angioimmunoblastic T-cell lymphoma (AILT), EBV-associated B-cell lymphoproliferative disorders have been reported. Here, we present two cases of EBV-associated B-cell lymphoma after treatment of T-cell lymphoma (AILT and peripheral T-cell lymphoma, unspecified, PTCL-NOS) with a regimen containing alemtuzumab and fludarabine. Conventional and immunohistological tissue staining showed the typical features of highly proliferating diffuse large B-cell lymphoma in both cases. The monoclonal B-cell population displayed EBV latency type III. At the time of diagnosis the cellular immune status of both patients was severely compromised with an absolute CD4 T-cell count below <120 microl(-1). Our observation supports the notion that combination of cytotoxic drugs and immunosuppressive antibodies in patients with T-cell lymphoma may severely aggravate the already present immunodeficiency. We suggest to monitor the cellular immune status in combination with the EBV load in high risk patients for early detection-and possibly intervention-of EBV-associated lymphoma.

• Authors: Katja C Weisel, Eckhart Weidmann, Ioannis Anagnostopoulos, Lothar Kanz, Antonio Pezzutto, Marion Subklewe
• Journal: International journal of hematology (Int J Hematol) Vol. 88 Issue 4 Pg. 434-440 (Nov 2008) ISSN: 1865-3774 [Electronic] Japan
• PMID: 18839273 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antibodies, Neoplasm
• Cytarabine
• Alemtuzumab

Topics

• Alemtuzumab
• Antibodies, Monoclonal (administration & dosage, adverse effects)
• Antibodies, Monoclonal, Humanized
• Antibodies, Neoplasm (administration & dosage, adverse effects)
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects)
• Cytarabine (administration & dosage, adverse effects)
• Epstein-Barr Virus Infections (chemically induced, pathology)
• Female
• Herpesvirus 4, Human
• Humans
• Lymphoma, Large B-Cell, Diffuse (chemically induced, pathology)
• Lymphoma, T-Cell (chemically induced, pathology)
• Male
• Middle Aged
• Neoplasms, Second Primary (drug therapy, pathology)
• Virus Latency (drug effects)